IRLAB Therapeutics – executive interview

Published on 13 June 2022

Based in Scandinavia, IRLAB Therapeutics is dedicated to discovering and developing new drugs for treating Parkinson’s disease and other life-altering illnesses that affect the central nervous system. In this interview, IRLAB’s executive vice president and head of R&D (previously CEO) Nicholas Waters provides an update on the company’s strategy and pipeline.

Share this with friends and colleagues